Abstract
Ticagrelor is a new oral antagonist of the platelet P2Y12 receptor that offers several potential advantages compared to clopidogrel including faster and more effective inhibition of platelet aggregation. Ticagrelor has been compared to clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial in a broad population of patients with acute coronary syndrome showing a reduction of the 12-month risk of death from vascular causes, myocardial infarction and stroke without increasing the overall risk of major bleeding. In a subanalysis of the PLATO trial focusing on patients with ST-elevation myocardial infarction, ticagrelor results were consistent with those of the overall trial. Additionally, possible pleiotropic effects of ticagrelor, including an appealing interaction with adenosine, might constitute a specific advantage in this particular subset of patients
Keywords: Ticagrelor, ST-elevation myocardial infarction, PLATO, P2Y12 receptor, clopidogrel, platelet aggregation, acute coronary syndrome, thrombolysis, percutaneous coronary intervention, thienopyridine
Current Vascular Pharmacology
Title:Ticagrelor in ST-Elevation Myocardial Infarction
Volume: 10 Issue: 4
Author(s): Gregory A. Sgueglia, Giuseppe Tarantini and Giampaolo Niccoli
Affiliation:
Keywords: Ticagrelor, ST-elevation myocardial infarction, PLATO, P2Y12 receptor, clopidogrel, platelet aggregation, acute coronary syndrome, thrombolysis, percutaneous coronary intervention, thienopyridine
Abstract: Ticagrelor is a new oral antagonist of the platelet P2Y12 receptor that offers several potential advantages compared to clopidogrel including faster and more effective inhibition of platelet aggregation. Ticagrelor has been compared to clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial in a broad population of patients with acute coronary syndrome showing a reduction of the 12-month risk of death from vascular causes, myocardial infarction and stroke without increasing the overall risk of major bleeding. In a subanalysis of the PLATO trial focusing on patients with ST-elevation myocardial infarction, ticagrelor results were consistent with those of the overall trial. Additionally, possible pleiotropic effects of ticagrelor, including an appealing interaction with adenosine, might constitute a specific advantage in this particular subset of patients
Export Options
About this article
Cite this article as:
A. Sgueglia Gregory, Tarantini Giuseppe and Niccoli Giampaolo, Ticagrelor in ST-Elevation Myocardial Infarction, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812728
DOI https://dx.doi.org/10.2174/157016112800812728 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotransmission Alterations in Central Cardiovascular Control in Experimental Hypertension
Current Hypertension Reviews Drug Therapy Aimed at Adenylyl Cyclase to Regulate Cyclic Nucleotide Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?
Current Pharmaceutical Design Perspectives of Activated Protein C in the Vasculature: Update on Proposed Roles of the Protein C Pathway
Current Genomics Angiotensin-(1-7): Blood, Heart, and Blood Vessels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Colchicine in Neurosurgery
Current Pharmaceutical Design Novel Conjugated Unsaturated Ketones with Submicromolar Potencies Towards some Leukemic and Colon Cancer Cells
Medicinal Chemistry Host-Cell Surface Binding Targets in SARS-CoV-2 for Drug Design
Current Pharmaceutical Design Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles
Current Medicinal Chemistry “Connecting the Dots” from Blood Brain Barrier Dysfunction to Neuroinflammation and Alzheimer’s Disease
Current Neurovascular Research Subject Index to Volume 1
Current Neurovascular Research Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus
Cardiovascular & Hematological Agents in Medicinal Chemistry The ATP-Binding Cassette Transporter-2 (ABCA2) Overexpression Modulates Sphingosine Levels and Transcription of the Amyloid Precursor Protein (APP) Gene
Current Alzheimer Research Problems and Perspectives of Abdominal Aortic Aneurysm Research
Current Drug Targets Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology Anti-Chlamydophila pneumoniae Antibodies as Associated Factor for Carotid Atherosclerosis in Patients with AIDS
Current HIV Research Neurological Disorders in Pregnancy
Current Women`s Health Reviews Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Formulation and <i>In vitro</i> Evaluation of Nystatin-loaded Albumin Microparticles for the Treatment of Leishmaniosis
Micro and Nanosystems The Renin-Angiotensin System in the Mammalian Central Nervous System
Current Protein & Peptide Science